key: cord-0895356-xh2efj4n authors: Tejedor Vaquero, S.; de Campos-Mata, L.; Ramada, J. M.; Diaz, P.; Navarro-Barriuso, J.; Ribas-Llaurado, C.; Rodrigo Melero, N.; Carolis, C.; Cerutti, A.; Gimeno, R.; Magri, G. title: SARS-CoV-2 naïve and recovered individuals show qualitatively different antibody responses following mRNA vaccination date: 2021-05-14 journal: nan DOI: 10.1101/2021.05.07.21256821 sha: dfecf7276008924646b947b35b3ccbb82da4f254 doc_id: 895356 cord_uid: xh2efj4n mRNA-based vaccines effectively induce protective neutralizing antibody responses against SARS-CoV-2, the etiological agent of COVID-19. The specific compositional patterns of these responses remain largely unknown. We found that SARS-CoV-2-naive individuals receiving the first dose of an mRNA vaccine developed a SARS-CoV-2-specific antibody response with a subclass profile comparable to that induced by the natural infection, except IgA2, which did not increase. SARS-CoV-2-naive subjects also mounted a robust virus-specific recall response after receiving the second dose. This response increased all IgG subclasses, but boosted neither IgM nor IgA1 and IgA2 subclasses. In contrast, individuals recovered from COVID-19 mounted peak virus-specific antibody responses upon primary immunization and did not further augment such responses following secondary immunization. Remarkably, compared to SARS-CoV-2-naive subjects, individuals with pre-existing immunity showed increased levels of all virus-specific antibodies but IgG3 following primary vaccination. By dissecting the heterogeneity of mRNA vaccine-induced humoral responses to SARS-CoV-2, our findings indicate that the induction of optimal immune protection may require the development of personalized vaccination programs. Vaccination against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS- is the leading option to achieve protection against the coronavirus disease 19 (COVID- 19 ) pandemic 1 . SARS-CoV-2 messenger RNA (mRNA)-based vaccines, such as the "mRNA-1273" from Moderna or the "BNT162b2" from Pfizer-BioNTech have been reported to be safe and highly effective in preventing severe COVID-19 disease in clinical trials 2, 3 . Hence, they have been recently approved for emergency use and are currently being administrated to millions of individuals in numerous Western countries. BNT162b2 and mRNA-1273 vaccines encode for the full-length spike (S) protein of SARS-CoV-2, which is essential for viral pathogenicity, and are applied in a two-dose immunization regimen, administered 21 days or 28 days apart, respectively. significantly higher S-and RBD-specific IgG titers, superior serum neutralization activity 7,11-13 , even against SARS-CoV-2 variants 8, 14, 15 , and increased S protein-specific memory T and B cell responses than naïve individuals [4] [5] [6] 14 . This enhanced response is consistent with the persistence of humoral and cellular immunity against SARS-CoV-2 in convalescent individuals, as previously reported [16] [17] [18] [19] [20] . Because a recall immunization does not seem to provide any quantitative benefit in subjects with pre-existing immunity to SARS-CoV-2 6, 7, 13 , it has been proposed that COVID-19 recovered people may only require a single vaccine dose to achieve optimal immune protection 6, 7, 13 . These studies have highlighted the importance of understanding the immunological history of an individual to evaluate the efficacy of vaccines against SARS-CoV-2. However, to date, the analysis of humoral responses to SARS-CoV-2 vaccines has exclusively focused on measuring S protein-specific total IgG responses. The contribution of virus-specific IgG subclasses and antibody classes different from IgG to vaccine-induced humoral responses remains elusive. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Recent studies, including ours 10, 16, 23 , have shown that IgG1 and IgG3 subclasses are indeed strongly induced soon after SARS-CoV-2 infection, whereas IgG2 and IgG4 subclasses are induced to a much lesser extent. In recovered individuals, humoral and B cell memory responses appeared to be IgG1-dominated 16, 19 . SARS-CoV-2 infection also induces virus-specific IgM, IgA1 and, to a lesser extent, IgA2, which all wane during convalescence 16 . How RBD-specific IgG and IgA subclasses are differentially induced upon administration of mRNA vaccines in SARS-CoV-2 naïve and recovered individuals is unknown. The characterization of vaccine-induced RBD-specific antibody profiles with subclass resolution may enhance our knowledge of humoral correlates of protection. Here we characterized serum RBD-specific antibody classes and subclasses, including All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. For this study, we recruited 48 healthy individuals who received SARS-CoV-2 mRNA vaccines (Moderna mRNA-1273 or Pfizer-BioNTech BNT162b2) at Parc Salut Mar (Barcelona, Spain). Of this cohort, 20 individuals had previous SARS-CoV-2 infection (mean age = 41; 75% female) and 28 were SARS-CoV-2 naïve (mean age = 37, 68% female) (Fig. 1A) . Sera were collected at three time points: pre-vaccine baseline (B), 2/3 weeks post the first dose (PFD), and one month post the second dose (PSD) (Fig. 1B) . To elucidate whether SARS-CoV-2 naïve and recovered individuals can mount comparable humoral responses to mRNA vaccines, we used a previously described 23, 24 two-step enzyme-linked immunosorbent assay (ELISA) that determines antibody responses to the RBD of the S protein from SARS-CoV-2. To quantitate antibodies, we individuals induced a significant increase of all RBD-specific IgG subclasses, which further increased following the second dose. As expected, the highest increase was observed for RBD-specific IgG1 and to a lesser extent, RBD-specific IgG3, whereas RBD-specific IgG2 and IgG4 showed much lower increases (Fig. 1C) . In subjects with pre-existing immunity, we also observed a significant increase of all RBD-specific IgG subclasses after the first dose of the mRNA vaccine; however, in these individuals the booster dose did not induce a further increase of any IgG subclasses (Fig. 1D) . We then compared the levels of anti-RBD IgG1, IgG3, IgG2 and IgG4 at baseline, after the first dose, and one month after the second dose between SARS-CoV-2 naïve and recovered individuals ( Fig. 1 E) . At baseline, study participants with prior history of infection showed significantly higher levels of RBD-specific IgG1 compared to SARS-CoV-2 naïve individuals. In contrast, no significant differences were observed between these two groups with respect to other IgG subclasses. After the first dose of an mRNA vaccine, RBD-specific IgG1, IgG2 and IgG4 titers in recovered individuals were significantly higher than in vaccinees with no pre-existing immunity to SARS-CoV-2. Interestingly, after primary immunization, the amount of RBD-specific IgG3 was similar in SARS-CoV-2 naïve and COVID-19 recovered individuals. Following the second dose of the vaccine, the concentrations of RBD-specific IgG1 and IgG4 were similar between the two groups of vaccinees, whereas RBD-specific IgG2 levels were still more elevated All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 14, 2021. ; https://doi.org/10.1101/2021.05.07.21256821 doi: medRxiv preprint in recovered individuals compared to SARS-CoV-2 naïve subjects. Remarkably, one month after the reboost, individuals with no prior history of SARS-CoV-2 infection showed slightly more RBD-specific IgG3 compared to recovered individuals (Fig. 1E) . Of note, we did not observe any relationship between sex and RBD-specific IgG subclasses at baseline, after the first immunization and after the recall immunization ( Fig. S1A ). Recent studies reported that mRNA vaccination induced S-specific IgA and IgM along with S-specific IgG in fully vaccinated individuals 12 . Moreover, circulating plasmablasts producing IgA anti-S were detected one week after the second dose of mRNA vaccine 25 . Yet, how S-specific IgM as well as IgA1 and IgA2 subclasses are differentially induced upon vaccination in SARS-CoV-2 naïve and COVID-19 recovered individuals remains unclear. Our analysis revealed that RBD-specific IgM increased after primary vaccination, but it did not further augment upon reboost in both groups of vaccinees ( Fig. 2A , B). We further evaluated the level of RBD-specific IgA1 and IgA2 subclasses. While IgA1 induction occurs in both mucosal and systemic compartments, IgA2 production is largely confined to the intestinal compartment 26 . Similarly to RBD-specific IgM, RBDspecific IgA1 was induced upon the first dose of vaccine in SARS-CoV-2 naïve and recovered individuals, but its serum concentration no longer augmented one month following the second dose ( Fig. 2A, B) . RBD-specific IgA2 titers were below the threshold at baseline and after the first and second dose of mRNA vaccine in SARS-CoV-2 naïve individuals ( Fig. 2A) , whereas a small but significant induction was observed in individuals with pre-existing immunity after primary but not secondary vaccination (Fig. 2B) . When we compared the levels of RBD-specific IgM, IgA1 and IgA2 in SARS-CoV-2 naïve and recovered individuals, we observed no significant differences at baseline, being most of AUC values below the threshold. However, after the first and second dose, individuals with prior history of SARS-CoV-2 infection showed significantly higher levels of RBD-specific IgM, IgA1 and IgA2 compared to SARS-CoV-2 naïve individuals (Fig. 2C) . Again, no association was observed between sex and RBD-specific IgM or IgA subclasses at any time points (Fig. S1B) . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Here, we showed that mRNA vaccination induced distinct profiles of subclass-specific antibody responses in SARS-CoV-2 naïve compared to COVID-19 recovered individuals. Our findings highlight both the complexity and heterogeneity of antibody responses to mRNA vaccines against SARS-CoV-2 in individuals with a different exposure history. Prior to vaccination, only RBD-specific IgG1 was significantly higher in COVID-19 recovered individuals compared to SARS-CoV-2 naïve subjects, which is consistent with the predominance of virus-specific IgG1 and memory B cell responses observed in COVID-19 convalescent individuals 16, 19 . Following primary immunization, individuals with pre-existing immunity showed increased titers of all RBD-specific antibodies, except IgG3, when compared to SARS-CoV-2 naïve subjects. This was consistent with the presence of pre-existing SARS-CoV-2-specific class-switched and unswitched memory B cells in COVID-19 recovered subjects 16, 17, 19, 20 . In line with our results, a recent report showed a strong correlation between the frequency of SARS-CoV-2-specific memory B cells at baseline and post-vaccination antibody levels 6 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Remarkably, differences in vaccine-induced antibody responses among SARS-CoV-2 naïve subjects and COVID-19 recovered individuals were also observed after recall immunization. In contrast to individuals with prior history of infection, SARS-CoV-2 naïve subjects showed a vigorous boosting of RBD-specific IgG responses upon the second dose of mRNA vaccination, which involved all IgG subclasses. Interestingly, after the second injection, RBD-specific IgG2 titers in SARS-CoV-2 naïve individuals were still significantly lower compared to those of recovered subjects, whereas IgG3 titers were significantly higher. The increased levels of RBD-specific IgG3 in SARS-CoV-2 naïve individuals could be due to the induction of increased number of IgG3 expressing memory B cells after primary vaccination or differences in the kinetics of humoral responses. Contrarily, no reboost effect was observed for RBD-specific IgM and IgA subclasses in both vaccinee groups, and the titers of these antibodies were consistently lower in fully vaccinated naïve subjects compared to recovered individuals. The lack of increased antibody response following recall vaccination in individuals with pre-existing immunity to SARS-CoV-2 is intriguing and could relate to the reduced antigen availability resulting from the elevated vaccine-specific IgG responses triggered by the primary immunization. However, it could also be due to differences in the kinetics of germinal center or extra follicular B cell responses to viral antigens as well as differences in the antigen-presenting cell priming. Such differences may influence the generation of secretory memory, including the generation of long-lived plasma cells in the bone marrow. Further studies are required to address these questions. In summary, our findings highlight the heterogeneity of mRNA vaccine-induced humoral responses to SARS-CoV-2. They also indicate that prior viral exposure may be the major determinant of this heterogeneity. Finally, they suggest that the induction of optimal immune protection may require the development of personalized vaccination programs. This study has the following limitations. First, the size of the studied cohort was small (n=48) and it only included SARS-CoV-2 recovered individuals who had experienced mild COVID-19 symptoms. Hence, our results should be confirmed in future larger-scale studies encompassing COVID-19 recovered individuals with more severe disease. In addition, all the participants of our study were below 65 years of age (mean = 39). Older SARS-CoV-2 naïve and COVID-19recovered individuals should be studied in the future to fully address the vaccine efficacy in this specific population. Finally, to fully investigate the protection offered by mRNA vaccines overtime, additional serologic measurements should be performed at later time points. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Further information and requests for resources and reagents should be directed to and will be fulfilled by the corresponding author, Giuliana Magri (gmagri@imim.es). 48 healthy individuals provided written consent and were enrolled in the study. All The pCAGGS RBD construct, encoding for the receptor-binding domain of the SARS- All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 14, 2021. ; https://doi.org/10.1101/2021.05.07.21256821 doi: medRxiv preprint Sera were collected from whole blood in silica-treated tubes where the blood was incubated for 30 min without movement to trigger coagulation. Next, samples were centrifuged for 10 min at 1300 g at room temperature (RT), heat-inactivated at 56ºC for 1 hour and stored at -20ºC prior to use. ELISAs performed in this study were adapted from previously established protocols 23 Negative threshold values were set for each immunoglobulin using naïve baseline AUC levels plus 2 times the standard deviations of the mean. Values below the background levels were replaced by the OD value of the blank. GraphPad Prism (version 8.0) was used to conduct statistical analyses. For each experiment, the type of statistical test, summary statistics and levels of significance were specified in the figures and corresponding legends. All tests were performed two-sided with a nominal significance threshold of p < 0.05. For comparisons between time points, paired tests were used. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. performed to compare SARS-CoV-2 naïve and recovered individuals (*P < 0.05, **P < 0.01, and ***P < 0.001). SARS-CoV-2 Naïve, n=28; SARS CoV-2 recovered, n=20. individuals (*P < 0.05, **P < 0.01, and ***P < 0.001). SARS-CoV-2 Naïve, n=28; SARS CoV-2 recovered, n=20. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. SARS-CoV-2 vaccines in development Safety and Efficacy of the BNT162b2 mRNA Covid-19 Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naïve and COVID-19 recovered individuals Durability of Responses after SARS-CoV-2 mRNA-1273 Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2 Neutralizing Antibodies against SARS-CoV-2 Variants after Infection and Vaccination Human neutralizing antibodies elicited by SARS-CoV-2 infection Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients Levels of produced antibodies after vaccination with mRNA vaccine; effect of previous infection with SARS-CoV-2. medRxiv mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science (80-. ) SARS-CoV-2 sculpts the immune system to induce sustained virus-specific naïve-like and memory B cell responses Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science (80-. ) Robust neutralizing antibodies to SARS-CoV-2 infection persist for months Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence Evolution of antibody immunity to SARS-CoV-2 IgG subclasses and allotypes: From structure to effector functions Beyond binding: Antibody effector functions in infectious diseases SARS-CoV-2-specific antibody profiles distinguish patients with moderate from severe A serological assay to detect SARS-CoV-2 seroconversion in humans SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation We would like to thank all the subjects who participated in our studies. This study was National Health Institute Carlos III (ISCIII) through the project COV20_00508 grant (Cofunded by European Regional Development Fund/European Social Fund "a way to make Europe) (to R.G.). All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted May 14, 2021. ; https://doi.org/10.1101/2021.05.07.21256821 doi: medRxiv preprint All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The authors declare that they have no competing financial interests.All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted May 14, 2021. ; https://doi.org/10.1101/2021.05.07.21256821 doi: medRxiv preprint